Neurology and Headache Societies Issue Updated Migraine Prevention Guidelines
The American Academy of Neurology and the American Headache Society have published an updated guideline to assist clinicians in selecting effective migraine prevention medications for adults. The guideline aims to improve treatment outcomes for chronic migraine sufferers.
The American Academy of Neurology (AAN) and the American Headache Society (AHS) have released updated guidelines for the prevention of migraine in adults. Published in the journal Neurology, these recommendations offer clinicians guidance on choosing the most effective pharmacological treatments.
Migraine is a chronic neurological disorder that significantly impacts patients' quality of life. The updated guidelines incorporate recent research and clinical evidence, addressing a range of medication classes. These include established treatments like certain blood pressure medications, anti-epileptic drugs, and antidepressants, as well as newer biologic therapies such as CGRP inhibitors.
The updated recommendations emphasize the importance of personalized treatment plans. Clinicians are advised to consider individual patient factors, including medical history, symptom severity, and potential contraindications, when selecting a preventative medication. The goal is to reduce the frequency and intensity of migraine attacks.
These updated guidelines are intended to enhance the quality and consistency of migraine prevention care. They provide a structured approach to medication selection, supporting healthcare providers in delivering optimal care for adults experiencing chronic migraines.